Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Open-Label, Active- and Placebo-Controlled Parallel Group Study of the Effect of Subcutaneous and Intravenous Methylnaltrexone on CYP450 2D6 Activity in Healthy Extensive Metabolizers of Dextromethorphan

NCT01367535 is registered in ClinicalTrials.gov with Bausch Health Americas, Inc. as lead sponsor.

NCT NCT01367535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01367535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Open-Label, Active- and Placebo-Controlled Parallel Group Study of the Effect of Subcutaneous and Intravenous Methylnaltrexone on CYP450 2D6 Activity in Healthy Extensive Metabolizers of Dextromethorphan
Lead sponsor
Bausch Health Americas, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2006
Completion date
August 31, 2006
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adults